Clinical Biostatistics & Data Analysis

Sample Size in Rare Disease and Small Population Clinical Programs Sample Size in Rare Disease and Small Population Clinical Programs Determining an appropriate sample size is a critical aspect of planning any clinical trial. This task becomes increasingly complex in the context of rare diseases and small population clinical programs where standard statistical methodologies may…

Read More “Sample Size in Rare Disease and Small Population Clinical Programs” »

Simulations for Complex Sample Size Scenarios in Modern Trial Designs Simulations for Complex Sample Size Scenarios in Modern Trial Designs In the evolving landscape of clinical research, the importance of precise sample size calculations has never been more pronounced. Modern trial designs often introduce complex scenarios, driven by the need for greater efficiency and necessity…

Read More “Simulations for Complex Sample Size Scenarios in Modern Trial Designs” »

Documenting Sample Size Justification in Protocol and SAP In clinical research management, sample size justification is a critical component of study protocols and Statistical Analysis Plans (SAP). This documentation ensures that the study is adequately powered to detect clinically meaningful effects while adhering to regulatory guidelines. Properly executed sample size calculations significantly influence the validity…

Read More “Documenting Sample Size Justification in Protocol and SAP” »

Common Pitfalls in Sample Size and Power Assumptions—and How to Avoid Them Common Pitfalls in Sample Size and Power Assumptions—and How to Avoid Them Sample size determination and power analysis are critical components of clinical trial design. Accurate assumptions in these areas can greatly influence the success or failure of a trial. This article aims…

Read More “Common Pitfalls in Sample Size and Power Assumptions—and How to Avoid Them” »

Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials In the evolving landscape of clinical research, innovative methodologies such as decentralized trials (DCT), hybrid trials, and pragmatic trial designs require precise strategies for sample size calculation. These trials differ in their execution and objectives,…

Read More “Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials” »

Using External and Real-World Data to Inform Sample Size Planning Effective sample size planning is crucial for the success of clinical trials, particularly when aiming to meet regulatory expectations from entities such as the FDA, EMA, and MHRA. This guide provides a step-by-step tutorial on how to leverage external and real-world data to inform sample…

Read More “Using External and Real-World Data to Inform Sample Size Planning” »

Global Regulatory Expectations for Sample Size Justification Global Regulatory Expectations for Sample Size Justification The determination of an appropriate sample size is a critical aspect of clinical trial design. It ensures that study findings are both statistically significant and clinically meaningful. Regulatory bodies across the US, UK, and EU provide guidelines that outline how sample…

Read More “Global Regulatory Expectations for Sample Size Justification” »

Case Studies: Underpowered vs Robustly Powered Clinical Programs Case Studies: Underpowered vs Robustly Powered Clinical Programs In clinical research, the significance of adequate sample size and power calculations cannot be overstated. Studies that are underpowered risk false negatives, hampering scientific discovery and regulatory approval, whereas robustly powered clinical programs enhance reliability and validation. This tutorial…

Read More “Case Studies: Underpowered vs Robustly Powered Clinical Programs” »

Case Studies: Underpowered vs Robustly Powered Clinical Programs Conducting robust clinical trials requires meticulous planning and a profound understanding of statistical principles, particularly sample size and power calculations. This article aims to guide clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU through a detailed exploration of the implications of…

Read More “Case Studies: Underpowered vs Robustly Powered Clinical Programs” »